Patent: 10,076,523
✉ Email this page to a colleague
Summary for Patent: 10,076,523
Title: | HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
Abstract: | This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects. |
Inventor(s): | Strum; Jay Copeland (Hillsborough, NC), Bisi; John Emerson (Chapel Hill, NC), Roberts; Patrick Joseph (Durham, NC), Tavares; Francis Xavier (Durham, NC) |
Assignee: | G1 Therapeutics, Inc. (Research Triangle Park, NC) |
Application Number: | 15/387,083 |
Patent Claims: | see list of patent claims |
Details for Patent 10,076,523
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2033-03-15 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2033-03-15 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2033-03-15 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |